Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival.
To further clarify the role of ribosomal protein S14 (RPS14) in myelodysplastic syndrome, we examined RPS14 transcription in bone marrow derived CD34+ cells from patients with non-5q- myelodysplastic syndrome and found a reduced expression of RPS14 in 51 of 72 (71%) patients. MDS patients with an intermediate-1 risk (INT-1) score according to the international prognostic scoring system and low RPS14 expression had a superior median overall survival of not reached versus 25 months compared to INT-1 patients with high RPS14 expression (p=0.0249). Using multivariate analysis, the RPS14 expression status was confirmed as an independent predictor for survival in INT-1 patients.
Czibere
Akos
A
Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf Moorenstrasse 5, 40225 Duesseldorf, Germany. Akos.Czibere@med.uni-duesseldorf.de
Bruns
Ingmar
I
Junge
Bärbel
B
Singh
Raminder
R
Kobbe
Guido
G
Haas
Rainer
R
Germing
Ulrich
U
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002869:Chromosome Aberrations; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000235:genetics* / Q000401:mortality*; D012042:Registries; D012269:Ribosomal Proteins / Q000235:genetics*; D015996:Survival Rate / Q000639:trends
D012269:Ribosomal Proteins; C039747:ribosomal protein S14